Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rituximab Biosimilar vs MMF in Childhood Steroid-dependent Nephrotic Syndrome
NCT04402580Phase 2Terminated
- Sponsor
- Istituto Giannina Gaslini
- Start
- Jul 2019
- Primary completion
- Aug 2020
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of rituximab in nephrotic syndrome, sponsored by Istituto Giannina Gaslini. Started Jul 2019; status: terminated.
02
Drugs
rituximab
03
Conditions
nephrotic syndrome
Beyond the preview
Go deeper on NCT04402580.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04402580.